Regulus shares spike on a high success rate for RG-101 hep C combos

John Carroll

Can still make a splash in the increasingly crowded hepatitis C drug market? The biotech says yes, backing up its case for RG-101 with interim Phase II data that showed its injection pushed a small group of patients to a 97% sustained virologic response after only four weeks of combination therapies using some of the top oral drugs now on the market.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS